Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

“Refractory spasticity, central neuropathic pain and bladder dysfunction are common clinical problems in patients with multiple sclerosis (MS). None of the currently available oral medications has proven to be reliably effective and can be limited by toxicity.

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis.

“We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS).

Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.

Several cardiometabolic factors present in obese and insulin-resistant individuals represent a continuum of increasing risk for the development of type 2 diabetes and cardiovascular disease.

Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?

Obesity is one of the highest preventable causes of morbidity and mortality in the developed world [1]. It has been well known for a long time that exposure to cannabis produces an increase of appetite (a phenomenon referred to as the 'munchies').

The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults

There are limited data regarding the relationship between cannabinoids and metabolic processes.

The interface: marijuana and body weight.

“Acute marijuana use is classically associated with snacking behavior (colloquially referred to as “the munchies”). In support of these acute appetite-enhancing effects, several authorities report that marijuana may increase body mass index in patients suffering from human immunodeficiency virus and cancer…

Obesity and Cannabis Use: Results From 2 Representative National Surveys

The role of cannabis and endocannabinoids in appetite regulation has been extensively studied, but the association of cannabis use with weight in the general population is not known.

The influence of cannabinoids on generic traits of neurodegeneration
“In an increasingly ageing population, the incidence of neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease are rising. While the aetiologies of these disorders are different, a number of common mechanisms that underlie their neurodegenerative components have been elucidated; namely neuroinflammation, excitotoxicity, mitochondrial dysfunction and reduced trophic support.

The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases

“Scientific evidence shows that an hypofunction or a dysregulation of the endocannabinoid system may be responsible for some of the symptoms of diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s, Parkinson’s and Alzheimer’s diseases.The aim of this review is to highlight the role of endocannabinoid system in neurodegenerative diseases.

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial.

“Parkinson’s disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons.… the endocannabinoid system has emerged as a promising target.…Our findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities…”

http://www.ncbi.nlm.nih.gov/pubmed/25237116  (PubMed)